| Not Yet Recruiting | Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory NCT07479979 | Natalie Callander | Phase 1 / Phase 2 |
| Not Yet Recruiting | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM NCT07377435 | David Avigan | Phase 1 |
| Not Yet Recruiting | FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple NCT07221032 | Medical College of Wisconsin | Phase 1 |
| Not Yet Recruiting | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treat NCT07463807 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor St NCT04579523 | Fred Hutchinson Cancer Center | Phase 1 |
| Not Yet Recruiting | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatm NCT06948084 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma NCT07082270 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relap NCT07181941 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma NCT07340853 | Thomas Martin, MD | Phase 1 |
| Recruiting | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleuce NCT07093554 | Medical College of Wisconsin | Phase 1 |
| Recruiting | Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcom NCT07045727 | Mayo Clinic | N/A |
| Recruiting | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma NCT06348108 | Alfred Chung, MD | Phase 1 |
| Recruiting | Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple NCT06940297 | Mayo Clinic | Phase 2 |
| Recruiting | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Pa NCT06627751 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractor NCT06232044 | Alliance for Clinical Trials in Oncology | Phase 1 / Phase 2 |
| Recruiting | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed NCT06622005 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma NCT06421675 | Ontario Clinical Oncology Group (OCOG) | Phase 2 |
| Recruiting | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elra NCT06799026 | David Avigan | Phase 1 |
| Withdrawn | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM NCT06352866 | Jack Khouri, MD | Phase 2 |
| Terminated | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma NCT06588660 | University of Washington | Phase 1 |
| Recruiting | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma NCT06465316 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM NCT06171685 | Multiple Myeloma Research Consortium | Phase 2 |
| Recruiting | Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM NCT06518551 | Omar Nadeem, MD | Phase 1 / Phase 2 |
| Recruiting | Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myelo NCT06433947 | Opna Bio LLC | Phase 1 |
| Terminated | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma NCT06304636 | Cartesian Therapeutics | Phase 1 |
| Recruiting | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma NCT05922501 | Massachusetts General Hospital | Phase 2 |
| Withdrawn | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT05950113 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Elranatamab in R/R Multiple Myeloma NCT06138275 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myelom NCT06203912 | Elvira Umyarova | Phase 1 |
| Recruiting | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multip NCT05896228 | Benjamin T Diamond, MD | Phase 2 |
| Recruiting | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple NCT05847569 | Mayo Clinic | Phase 2 |
| Recruiting | Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BC NCT05981209 | Abdullah Khan | Phase 1 |
| Recruiting | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Can NCT06119685 | Indapta Therapeutics, INC. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Ce NCT05742217 | Pfizer | — |
| Terminated | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) NCT05641324 | Anaveon AG | Phase 1 |
| Terminated | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor NCT05117008 | Medical College of Wisconsin | Phase 2 |
| Active Not Recruiting | A Study of MCARH109 and MCARH125 in People With Multiple Myeloma NCT05431608 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma NCT05430945 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab NCT05053607 | Pack Health | N/A |
| Withdrawn | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma NCT05170789 | Tulane University School of Medicine | Phase 2 |
| Withdrawn | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ an NCT06400264 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refract NCT04843579 | Weill Medical College of Cornell University | Phase 2 |
| Completed | A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. NCT05228470 | Pfizer | Phase 2 |
| Active Not Recruiting | A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma NCT04302324 | Weill Medical College of Cornell University | Phase 2 |
| Active Not Recruiting | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma NCT05577000 | Thomas Martin, MD | Phase 1 |
| Recruiting | TriPRIL CAR T Cells in Multiple Myeloma NCT05020444 | Marcela V. Maus, M.D.,Ph.D. | Phase 1 |
| Active Not Recruiting | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple NCT04883242 | University of Washington | Phase 2 |
| Unknown | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma NCT05150522 | Shenzhen University General Hospital | Phase 1 / Phase 2 |
| Withdrawn | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma NCT04355039 | Medical College of Wisconsin | Phase 1 |
| Withdrawn | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma NCT04802031 | Thomas Martin, MD | Phase 2 |
| Active Not Recruiting | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Rela NCT04764942 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed a NCT04790474 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Completed | A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma NCT04398485 | Ionis Pharmaceuticals, Inc. | Phase 1 |
| Not Yet Recruiting | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma NCT04670055 | Zhejiang University | EARLY_Phase 1 |
| Unknown | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. NCT04519476 | Oncotherapeutics | Phase 1 |
| Completed | A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed NCT04434469 | Genentech, Inc. | Phase 1 |
| Recruiting | Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM NCT04176718 | Andrew Yee, MD | Phase 2 |
| Terminated | Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma NCT04119336 | Andrew Yee, MD | Phase 2 |
| Completed | Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to NCT03770260 | National Cancer Institute (NCI) | Phase 1 |
| Completed | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) NCT04083534 | Regeneron Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma NCT03702725 | Alliance Foundation Trials, LLC. | Phase 1 |
| Active Not Recruiting | Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol NCT06400251 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Sub NCT06400225 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory NCT03798678 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma NCT04162353 | iCell Gene Therapeutics | Phase 1 |
| Unknown | Carfilzomib in Combination for the Treatment of RR MM NCT04004338 | Black Sea Hematology Association | — |
| Completed | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refracto NCT03952091 | TJ Biopharma Co., Ltd. | Phase 3 |
| Completed | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma NCT03860038 | TJ Biopharma Co., Ltd. | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H NCT06400238 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma NCT03520985 | Swiss Cancer Institute | Phase 2 |
| Completed | Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or R NCT03731832 | GWT-TUD GmbH | Phase 2 |
| Unknown | Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans NCT03601624 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | Phase 2 |
| Active Not Recruiting | Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MAT NCT06308822 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma NCT03589222 | PETHEMA Foundation | Phase 2 |
| Active Not Recruiting | Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) NCT05490771 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma NCT03031730 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patie NCT03618602 | Shanghai Theorion Pharmaceutical Co Ltd. | Phase 1 |
| Active Not Recruiting | Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A NCT06385483 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma NCT03266692 | Cogent Biosciences, Inc. | Phase 1 |
| Terminated | Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma NCT03201250 | University of Nebraska | Phase 1 / Phase 2 |
| Active Not Recruiting | High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Rel NCT03389347 | University of Washington | N/A |
| Completed | Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myel NCT03158688 | Amgen | Phase 3 |
| Active Not Recruiting | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) NCT04439227 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subp NCT06385496 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATC NCT06390865 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z NCT06390852 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma NCT02998047 | Actinium Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol NCT06390826 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol NCT06357975 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MAT NCT06360575 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol NCT04439344 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) NCT04439123 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N NCT04439149 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotoco NCT04439188 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-S NCT04439175 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1 NCT04439318 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subp NCT04439357 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant NCT06357988 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) NCT06303167 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subp NCT04439331 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATC NCT04439110 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G NCT04439253 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) NCT04439266 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R NCT04439279 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATC NCT04439292 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) NCT04439136 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Ref NCT02101944 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT02199665 | University of Chicago | Phase 1 |
| Completed | Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple M NCT02103335 | Celgene | Phase 1 |
| Withdrawn | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Maligna NCT01652014 | University of Medicine and Dentistry of New Jersey | Phase 2 |
| Terminated | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myel NCT01954784 | Case Comprehensive Cancer Center | Phase 1 |
| Terminated | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy NCT02020941 | Attaya Suvannasankha | Phase 2 |
| Completed | Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib NCT01775553 | Ajai Chari | Phase 2 |
| Withdrawn | Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell NCT01812720 | Mayo Clinic | Phase 2 |
| Terminated | Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy NCT01676961 | NYU Langone Health | Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide a NCT01564537 | Takeda | Phase 3 |
| Completed | Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients NCT01653106 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Tr NCT01534143 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma NCT01447914 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT01212952 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple NCT02037256 | Barbara Ann Karmanos Cancer Institute | N/A |
| Terminated | Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenal NCT01301963 | Case Comprehensive Cancer Center | Phase 3 |
| Completed | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignanci NCT01658319 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia NCT01118689 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With NCT01078441 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Completed | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilizati NCT01110135 | University of Washington | Phase 2 |
| Completed | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma NCT01083602 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma NCT01155583 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Terminated | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Bloo NCT01076270 | Fred Hutchinson Cancer Center | N/A |
| Completed | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lympho NCT01129193 | Amir Mortazavi | Phase 1 |
| Completed | Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myel NCT01074060 | City of Hope Medical Center | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Mye NCT01034553 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myelom NCT01049945 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Und NCT00998049 | Mayo Clinic | Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT01096342 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hod NCT00918333 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma NCT00693433 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Pat NCT00849251 | University of Washington | Phase 1 / Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Terminated | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00719901 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Trans NCT00619684 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma NCT00912899 | Cougar Biotechnology, Inc. | Phase 1 |
| Completed | Sunitinib in Treating Patients With Relapsed Multiple Myeloma NCT00514137 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma NCT00398515 | National Cancer Institute (NCI) | Phase 1 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00253578 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma NCT00112723 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer NCT00303797 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00310024 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma NCT00243035 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance NCT00217438 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma NCT00124605 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant NCT00114101 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous St NCT00112827 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin' NCT00118170 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multip NCT00306813 | University of Wuerzburg | Phase 1 / Phase 2 |
| Completed | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma NCT00153933 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00079456 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated W NCT00182663 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer NCT00060372 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction NCT00054483 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients Wi NCT00054353 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT00047203 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors NCT00028821 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Pat NCT00006244 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Pa NCT00003954 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Bryostatin and Vincristine in B-Cell Malignancies NCT00003166 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte I NCT00003196 | Fred Hutchinson Cancer Center | N/A |
| Completed | Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation NCT00002787 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 1 |
| Completed | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patient NCT01177371 | Case Comprehensive Cancer Center | Phase 2 |
| Withdrawn | GO-203-2C + Bortezomib For Relapsed Or Refractory MM NCT02658396 | Dana-Farber Cancer Institute | Phase 1 |
| Withdrawn | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma NCT00995059 | Mayo Clinic | Phase 1 / Phase 2 |